TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22778122

Group type: EXPERIMENTAL
Intervention: Meditation (n = 51)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Exercise (n = 47)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control (n = 51)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Comparison of meditation vs control
Number of subjects: 154

Group type: COMPARATOR
Intervention: Comparison of exercise vs control
Number of subjects: 154
Study: 20472939

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 1316

Group type: COMPARATOR
Intervention: Surfactant treatment
Number of subjects: 1316
Study: 18762591

Group type: EXPERIMENTAL
Intervention: Family-focused treatment for adolescents (FFT-A) and protocol pharmacotherapy (n = 30)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Enhanced care (EC) and protocol pharmacotherapy (n = 28)
Number of subjects: 58
Study: 16856132

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA) immediately reconstituted with saline
Number of subjects: 32

Group type: COMPARATOR
Intervention: Botulinum toxin A (BTA) stored in refrigerator for 1 week or more
Number of subjects: 32
Study: 12047055

Group type: EXPERIMENTAL
Intervention: Learning items by rote
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Performing a short‐term matching task
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Searching for the rules of the grammar
Number of subjects: 78
Study: 10418657

Group type: EXPERIMENTAL
Intervention: Clinical interventions including advice to re-engage in activity, support to develop personalized goals, reinforcement for healthy gains and appropriate functional activities, and physical conditioning exercises.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Interventions promoting communication at the work-site or modifying the patient's job.
Number of subjects: 16
Study: 7887641

Group type: EXPERIMENTAL
Intervention: TAP-144-SR 3.75mg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: TAP-144-SR 7.5mg
Number of subjects: 95
Study: 19256131

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 335000

Group type: EXPERIMENTAL
Intervention: Whole-virus vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Split-product vaccine
Number of subjects: 0
Study: 31518717

Group type: EXPERIMENTAL
Intervention: Magnetic Sphincter Augmentation (MSA)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 152
Study: 31263057

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg/day)
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: High-dose aspirin (325 mg/day)
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 1121
Study: 28713729

Group type: EXPERIMENTAL
Intervention: Piezotome (Piezosurgery)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional rotatory osteotomy
Number of subjects: 30
Study: 25833022

Group type: EXPERIMENTAL
Intervention: Idazoxan (40 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 23369221

Group type: EXPERIMENTAL
Intervention: Volumetric Modulated Arc Therapy (VMAT)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Number of subjects: 5
Study: 21610123

Group type: EXPERIMENTAL
Intervention: diacerein (50 mg once daily for the first 15 days and twice daily for 45 additional days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: diacerein
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 19492999

Group type: EXPERIMENTAL
Intervention: Topical application of green tea
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical application of white tea
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no tea application)
Number of subjects: 0
Study: 16541308

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) using a combination of radiopharmaceutical 99mTc‐albumin colloid and Patent Blue V dye
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) using blue dye
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) using isotope
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) using a combination of blue dye and isotope
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) in patients with grade 3 tumors
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) in patients with grade 2 tumors
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) with one SLN harvested
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB) with multiple SLNs (three or more) removed
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Number of subjects: 842
Study: 15155044

Group type: EXPERIMENTAL
Intervention: D.A.R.E. Plus multicomponent intervention
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: D.A.R.E. middle school curriculum
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 12243706

Group type: EXPERIMENTAL
Intervention: Tretinoin gel microsphere 0.1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adapalene gel 0.1%
Number of subjects: 0
Study: 10984871

Group type: EXPERIMENTAL
Intervention: Bedside wellness system (BSW) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 8858320

Group type: EXPERIMENTAL
Intervention: Pneumatic dilation
Number of subjects: 29

Group type: COMPARATOR
Intervention: Botulinum toxin injection
Number of subjects: 29
Study: 1644335

Group type: EXPERIMENTAL
Intervention: 4-aminosalicylic acid (4-ASA) 2 g enemas
Number of subjects: 45

Group type: COMPARATOR
Intervention: Prednisolone 20 mg enemas
Number of subjects: 45
Study: 6092557

Group type: EXPERIMENTAL
Intervention: Lithium treatment (40 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (60 patients without lithium)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lithium treatment with bronchodilators
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lithium treatment (with or without bronchodilators)
Number of subjects: 100
Study: 29288501

Group type: EXPERIMENTAL
Intervention: Iodine supplementation (10 grams of iodized salt daily)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Iodine restriction (noniodized salt with low-iodine or noniodine diet)
Number of subjects: 405
Study: 26281955

Group type: EXPERIMENTAL
Intervention: Errorless goal management training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional goal management training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 60
Study: 24385534

Group type: EXPERIMENTAL
Intervention: Deferasirox (target dose 40 mg/kg per day)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Deferoxamine (50‐60 mg/kg per day for 5‐7 days/week)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 197

Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 197
Study: 23302669

Group type: EXPERIMENTAL
Intervention: Micro invasive occlusion procedure
Number of subjects: 220

Group type: COMPARATOR
Intervention: Traditional cardiopulmonary bypass surgery
Number of subjects: 220
Study: 20456627

Group type: EXPERIMENTAL
Intervention: couple lubricants (1 lubricant for female and second lubricant for male partner)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: female arousal gel
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: female lubricant
Number of subjects: 326

Group type: COMPARATOR
Intervention: no intervention
Number of subjects: 326
Study: 17972477

Group type: EXPERIMENTAL
Intervention: Three-level hierarchical letter stimuli
Number of subjects: 0
Study: 16336447

Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg midazolam
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 0.06 mg/kg midazolam
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 0.09 mg/kg midazolam
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 12201618

Group type: EXPERIMENTAL
Intervention: Mix25 (25% insulin lispro and 75% NPL)
Number of subjects: 37
Study: 9473965

Group type: EXPERIMENTAL
Intervention: Experimental group with higher fat and zinc diets
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Original intervention
Number of subjects: 56
Study: 8554280

Group type: EXPERIMENTAL
Intervention: Manual inflating balloon cannula (group I)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Self-inflating balloon cannula (group II)
Number of subjects: 54
Study: 2677259

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 0
Study: 30293464

Group type: EXPERIMENTAL
Intervention: Internally cooled wet (ICW) electrodes
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Internally cooled wet (ICW) electrodes with saline infusion
Number of subjects: 17
Study: 29753033

Group type: EXPERIMENTAL
Intervention: Nemolizumab 0.1 mg/kg Q4W
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Nemolizumab 0.5 mg/kg Q4W
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Nemolizumab 2.0 mg/kg Q4W
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Nemolizumab 2.0 mg/kg Q8W
Number of subjects: 264
Study: 26851059

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation (ETI)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT) insertion
Number of subjects: 3000
Study: 24749682

Group type: EXPERIMENTAL
Intervention: Verbal encouragement during the 6-minute walk test (6MWT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No verbal encouragement during the 6-minute walk test (6MWT)
Number of subjects: 80
Study: 22512763

Group type: EXPERIMENTAL
Intervention: Positive-content message
Number of subjects: 2

Group type: COMPARATOR
Intervention: Negative-content message
Number of subjects: 2
Study: 19961017

Group type: EXPERIMENTAL
Intervention: TEA + GA (thoracic epidural anesthesia combined with general anesthesia)
Number of subjects: 44

Group type: COMPARATOR
Intervention: TIVA (total intravenous anesthesia)
Number of subjects: 44
Study: 17980419

Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) supplementation with 0.5 g of docosahexaenoic acid and 0.15 g of eicosapentaenoic acid, 400 mug of methyl‐tetra‐hydrofolic acid
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) supplementation
Number of subjects: 311
Study: 16202012

Group type: EXPERIMENTAL
Intervention: Rheopheresis treatment
Number of subjects: 6
Study: 12394562

Group type: EXPERIMENTAL
Intervention: Home visits to patients' homes
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Home visits
Number of subjects: 21
Study: 10339805

Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bone marrow graft stem cells
Number of subjects: 0
Study: 8951937

Group type: EXPERIMENTAL
Intervention: 300 mg tolperisone hydrochloride
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 2009058

Group type: EXPERIMENTAL
Intervention: 1-cm-margin excision
Number of subjects: 612

Group type: COMPARATOR
Intervention: Wide excision (margins of greater than or equal to 3 cm)
Number of subjects: 612
Study: 6804108

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 17
Study: 31929122

Group type: EXPERIMENTAL
Intervention: Gocovri (amantadine) 274 mg once daily at bedtime
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Gocovri (amantadine)
Number of subjects: 223
Study: 31778629

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C (1.5 g every 6 hours)
Number of subjects: 21
Study: 29052559

Group type: EXPERIMENTAL
Intervention: Niaoduqing particles 5 g thrice daily and 10 g before bedtime for 24 weeks
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo administered using the same methods for 24 weeks
Number of subjects: 300
Study: 26174334

Group type: EXPERIMENTAL
Intervention: Psychoeducation (6 weekly sessions)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Physical exercise (6 weekly sessions)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Enhanced treatment as usual
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 209
Study: 23137995

Group type: EXPERIMENTAL
Intervention: CoJet/Clearfil Ceramic Primer/Panavia F2.0/10d
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clearfil Esthetic Cement with CoJet
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Panavia F2.0 with CoJet
Number of subjects: 15

Group type: COMPARATOR
Intervention: Clearfil Esthetic Cement without CoJet
Number of subjects: 15

Group type: COMPARATOR
Intervention: Panavia F2.0 without CoJet
Number of subjects: 15
Study: 20737411

Group type: EXPERIMENTAL
Intervention: Communication skills training (CST) of nurses
Number of subjects: 89
Study: 19137409

Group type: EXPERIMENTAL
Intervention: Bicarbonate (Bi) infusion in dextrose water
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral acetazolamide (AZ) with normal saline (NLS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (NLS) infusion alone
Number of subjects: 0
Study: 17507633

Group type: EXPERIMENTAL
Intervention: Adjuvant taxane-anthracycline-containing chemotherapy and/or trastuzumab (Herceptin)
Number of subjects: 26
Study: 15054078

Group type: COMPARATOR
Intervention: Normal-appearing pyramidal neurons from non-CD tissue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytomegalic neurons from CD tissue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyramidal neurons in CD tissue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytomegalic neurons and normal-appearing pyramidal neurons from CD tissue
Number of subjects: 0
Study: 11443793

Group type: EXPERIMENTAL
Intervention: Endoscopic laser foraminoplasty
Number of subjects: 250
Study: 9595988

Group type: EXPERIMENTAL
Intervention: OPC-14117 60 mg/d
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: OPC-14117 120 mg/d
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: OPC-14117 240 mg/d
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 8113252

Group type: EXPERIMENTAL
Intervention: Harris‐Galante acetabular component inserted without cement
Number of subjects: 21

Group type: COMPARATOR
Intervention: Charnley acetabular component fixed with cement
Number of subjects: 21
Study: 2539017

Group type: EXPERIMENTAL
Intervention: Enalapril (20 to 40 mg daily)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Atenolol (50 to 100 mg daily)
Number of subjects: 162
Study: 28986515

Group type: EXPERIMENTAL
Intervention: Pharmacists
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Pharmacy Technicians
Number of subjects: 306

Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 306
Study: 26486418

Group type: EXPERIMENTAL
Intervention: Diabetes patients with any type of diabetic retinopathy (DR) and/or maculopathy
Number of subjects: 2806

Group type: EXPERIMENTAL
Intervention: Diabetes patients with sight-threatening diabetic retinopathy
Number of subjects: 2806

Group type: EXPERIMENTAL
Intervention: Known diabetics without regular eye examinations for DR
Number of subjects: 2806

Group type: EXPERIMENTAL
Intervention: Known diabetics with last eye examination >24 months ago
Number of subjects: 2806

Group type: COMPARATOR
Intervention: Hindustani individuals compared to other ethnic groups
Number of subjects: 2806
Study: 23652333

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted pylorus-preserving gastrectomy (LAPPG)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 292

Group type: COMPARATOR
Intervention: LADG
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: LAPPG
Number of subjects: 292
Study: 23537617

Group type: EXPERIMENTAL
Intervention: GnRH agonist (goserelin) for 3 months (Group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Total Abdominal Hysterectomy (TAH) (Group 2)
Number of subjects: 80
Study: 19691907

Group type: EXPERIMENTAL
Intervention: 50 mg quetiapine XR
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: 150 mg quetiapine XR
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: 20 mg paroxetine
Number of subjects: 873

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 873
Study: 18624596

Group type: EXPERIMENTAL
Intervention: Hypertension label
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Medication, reducing salty foods, and losing weight
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Low trust in physicians with unfamiliar disease label
Number of subjects: 152
Study: 15780844

Group type: EXPERIMENTAL
Intervention: D-serine (30 mg/kg/day)
Number of subjects: 39
Study: 11870242

Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (0.25 mg, 0.5 mg, 1 mg at three-month intervals; 4 mg as a single dose; 2 mg doses six months apart)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study: 10195357

Group type: EXPERIMENTAL
Intervention: Cetirizine (20 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dimethindene (4 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Substance P (SP)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide (CGRP)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: H1-antagonists (Cetirizine and Dimethindene)
Number of subjects: 27
Study: 7850984

Group type: EXPERIMENTAL
Intervention: 0.8 mg/h transdermal nitroglycerin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 12
Study: 1691125

Group type: EXPERIMENTAL
Intervention: Laser therapy only
Number of subjects: 46

Group type: COMPARATOR
Intervention: Laser therapy followed by endoscopic intubation
Number of subjects: 46
Study: 7361087

Group type: EXPERIMENTAL
Intervention: Diflunisal (500-750 mg daily)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (2000-3000 mg daily)
Number of subjects: 38
Study: 31520045

Group type: EXPERIMENTAL
Intervention: Electronic two-week rule (2WR) referrals compliant with NICE NG12 guidelines
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Patients seen within two weeks after referral
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Detection of malignancy from referrals
Number of subjects: 219
Study: 27991810

Group type: EXPERIMENTAL
Intervention: Standard CCET (15 hours face to face)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Compact CCET (12 hours face to face)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Short CCET (self-learning DVD + 8 hours face to face)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 159
Study: 25481453

Group type: EXPERIMENTAL
Intervention: 4-week taper condition (N=22)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: H(+) participants
Number of subjects: 89

Group type: COMPARATOR
Intervention: H(-) participants
Number of subjects: 89
Study: 23404180

Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA) performed annually
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (no CGA)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: CGA
Number of subjects: 1000
Study: 20506328

Group type: EXPERIMENTAL
Intervention: Drug Eluting Stents (DES)
Number of subjects: 1537

Group type: COMPARATOR
Intervention: Bare Metal Stents (BMS)
Number of subjects: 1537
Study: 19378676

Group type: EXPERIMENTAL
Intervention: TAXUS Express MR stent
Number of subjects: 446

Group type: COMPARATOR
Intervention: Uncoated Express Control stent
Number of subjects: 446
Study: 17239942

Group type: EXPERIMENTAL
Intervention: 2 ml Patent Blue diluted with 8 ml NaCl 0.9%
Number of subjects: 60

Group type: COMPARATOR
Intervention: 4 ml Patent Blue (standard labelling volume)
Number of subjects: 60
Study: 15525310

Group type: EXPERIMENTAL
Intervention: Vitapex
Number of subjects: 52

Group type: COMPARATOR
Intervention: Zinc oxide and eugenol (ZOE)
Number of subjects: 52
Study: 12541860

Group type: EXPERIMENTAL
Intervention: Herba Houttuyniae irrigation liquid
Number of subjects: 192

Group type: COMPARATOR
Intervention: Other irrigation liquids (not specified)
Number of subjects: 192
Study: 9714946

Group type: EXPERIMENTAL
Intervention: Danger ideation reduction therapy (DIRT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Wait list (Control)
Number of subjects: 21
Study: 7992096

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy (CVD) plus interleukin-2 (IL-2) and interferon-alfa (IFN-alpha)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biotherapy (IL-2 plus IFN-alpha) administered immediately after CVD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biotherapy (IL-2 plus IFN-alpha) administered in a sandwich of biotherapy/CVD/biotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biotherapy (IL-2 plus IFN-alpha) administered concurrently with CVD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin-based regimen with IL-2 plus IFN-alpha
Number of subjects: 0
Study: 3124651

Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Operative gastrostomy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy (with tube replacement)
Number of subjects: 48